Supported by an educational grant from Axsome Therapeutics, Inc.

News

Pharmacogenomic Test Improves MDD Response and Remission Outcomes

Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with

All News

FDA Approves TMS Device for Major Depressive Disorder in Adolescents

The US Food and Drug Administration (FDA) approved on Wednesd

High Levels of THC in Cannabis Products Associated With Mental Health Risks

Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis,

Child Depression During COVID-19 Pandemic Associated With Subsequent Maternal Depression

According to study results published in JAMA Pediatrics, child depression

Vulnerability to Inflammation-Related Depression Exaggerated in Older Adults With Insomnia

Compared with older adults without insomnia, older adults with the sleep disorder exper

Recent Cohort Study Assesses Genetic Relationships Between Psychotic Disorders

From a genetic perspective, delusional disorder (DD), acute psychoses (AP), psychosis otherwise not specified (PNOS), and schizoaffective disorder (SAD) do not appear to be subtypes of

Psilocybin May Improve Outcomes More Than Traditional MDD Treatments

While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in

Evidence Lacking for TRD Treatment Effectiveness in Older Adults, Review Finds

A systematic review published in BMJ Mental Health found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological intervent

Post Partum Hormonal Contraception Use Linked With Heightened Depression Risk

The initiation of hormonal contraception post partum was associated with an immediate increase in

New Study Finds Quetiapine More Effective Than Lithium in Reducing Treatment-Resistant Depression Symptoms

Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of